Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Hajime Asahina,Satoshi Oizumi,Akira Inoue,Ichiro Kinoshita,Takashi Ishida,Yuka Fujita,Noriaki Sukoh,Masao Harada,Makoto Maemondo,Yasuo Saijo,Hirotoshi Dosaka-Akita,Hiroshi Isobe,Toshihiro Nukiwa,Masaharu Nishimura

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

2010

Hajime Asahina
Satoshi Oizumi
Akira Inoue
Ichiro Kinoshita
Takashi Ishida
Yuka Fujita
Noriaki Sukoh
Masao Harada
Makoto Maemondo
Yasuo Saijo
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Toshihiro Nukiwa
Masaharu Nishimura

Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previou

Keywords:

non-small cell lung cancer (NSCLC)
Immunology
Phases of clinical research
Progression-free survival
Cancer
Epidermal growth factor receptor
Gefitinib
Medicine
Tyrosine-kinase inhibitor
Lung cancer
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations